Meeting
2020 ASCO Virtual Scientific Program
Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.
Authors
D. Ross Camidge
Division of Medical Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO
D. Ross Camidge , Huifeng Niu , Hye Ryun Kim , James Chih-Hsin Yang , Myung-Ju Ahn , Jacky Yu-Chung Li , Maximilian Hochmair , Angelo Delmonte , Alexander I. Spira , Rosario Garcia Campelo , Fabrice Barlesi , Geoffrey Liu , Marcello Tiseo , Cong Li , Miguel Williams , Hyunjin Shin , Pingkuan Zhang , Sanjay Popat
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02737501
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9517)
DOI
10.1200/JCO.2020.38.15_suppl.9517
Abstract #
9517
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.
First Author: Kaushal Parikh
Poster
2021 ASCO Annual Meeting
Circulating tumor DNA to investigate resistance mechanism and clone evolution of ALK TKI treated lung adenocarcinoma.
First Author: Gang Hua
Poster
2020 ASCO Virtual Scientific Program
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
First Author: Minsuk Kwon
Poster
2022 ASCO Annual Meeting
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
First Author: Alessandra Bearz